BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $129.5625.

Several equities research analysts have recently commented on the stock. Berenberg Bank lowered their price objective on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Citigroup lowered their price objective on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and set a $130.00 price objective on shares of BioNTech in a research note on Monday, April 27th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th.

BioNTech Trading Down 0.5%

NASDAQ:BNTX opened at $90.21 on Thursday. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The firm has a fifty day simple moving average of $94.29 and a 200-day simple moving average of $98.01. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $22.81 billion, a P/E ratio of -15.34 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The company had revenue of $1.06 billion for the quarter. On average, equities research analysts anticipate that BioNTech will post -5.67 earnings per share for the current year.

BioNTech declared that its board has initiated a share repurchase plan on Thursday, May 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC lifted its position in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. EFG International AG acquired a new position in BioNTech during the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd lifted its position in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares during the period. Huntington National Bank lifted its position in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.